Kezar Life Sciences (KZR) Stock Price, News & Analysis

Company Overview

Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

Key Stats

• Today's Range: $7.45 to $7.58
• 50-Day Range: $5.29 to $8.95
• 52-Week Range: $5.20 to $11.35
• Volume: 106,671 shs
• Average Volume: 67,698 shs
• Market Capitalization: $54.68 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $40.50
• Consensus Rating: Hold

Kezar Life Sciences Stock Analysis - MarketRank™

Kezar Life Sciences scored higher than 87% of companies evaluated by MarketBeat, and ranked 134th out of 963 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.0 / 5
• Analyst Rating: Hold

Consensus Rating

Kezar Life Sciences has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 3 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Kezar Life Sciences has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Kezar Life Sciences are expected to decrease in the coming year, from ($6.30) to ($7.78) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Kezar Life Sciences is -0.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Kezar Life Sciences is -0.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Kezar Life Sciences has a P/B Ratio of 0.41. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.87% of the float of Kezar Life Sciences has been sold short.

Short Interest Ratio / Days to Cover

Kezar Life Sciences has a short interest ratio ("days to cover") of 1.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Kezar Life Sciences has recently decreased by 85.04%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Kezar Life Sciences does not currently pay a dividend.

Dividend Growth

Kezar Life Sciences does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.6 / 5
• Environmental Score: -0.85

Percentage of Shares Shorted

2.87% of the float of Kezar Life Sciences has been sold short.

Short Interest Ratio / Days to Cover

Kezar Life Sciences has a short interest ratio ("days to cover") of 1.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Kezar Life Sciences has recently decreased by 85.04%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.5 / 5
• News Sentiment: 0.46

News Sentiment

Kezar Life Sciences has a news sentiment score of 0.46. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 9 news articles for Kezar Life Sciences this week, compared to 1 article on an average week.

MarketBeat Follows

1 people have added Kezar Life Sciences to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Kezar Life Sciences insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 9.30% of the stock of Kezar Life Sciences is held by insiders.

Percentage Held by Institutions

67.90% of the stock of Kezar Life Sciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

KZR Stock Analysis - Frequently Asked Questions

How have KZR shares performed this year?

Kezar Life Sciences' stock was trading at $9.4740 at the beginning of the year. Since then, KZR stock has decreased by 20.9% and is now trading at $7.49.
View the best growth stocks for 2024 here.

How were Kezar Life Sciences' earnings last quarter?

Kezar Life Sciences, Inc. (NASDAQ:KZR) announced its quarterly earnings data on Tuesday, November, 12th. The company reported ($2.78) earnings per share for the quarter, topping the consensus estimate of ($3.03) by $0.25.

When did Kezar Life Sciences' stock split?

Kezar Life Sciences's stock reverse split before market open on Wednesday, October 30th 2024. The 1-10 reverse split was announced on Monday, October 28th 2024. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, October 29th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

When did Kezar Life Sciences IPO?

Kezar Life Sciences (KZR) raised $70 million in an initial public offering on Thursday, June 21st 2018. The company issued 4,700,000 shares at a price of $14.00-$16.00 per share. Jefferies, Cowen, Wells Fargo Securities and William Blair acted as the underwriters for the IPO.

Who are Kezar Life Sciences' major shareholders?

Kezar Life Sciences' top institutional investors include Stonepine Capital Management LLC (20.43%), Ikarian Capital LLC (14.64%), Geode Capital Management LLC (8.59%) and Sphera Funds Management LTD. (2.81%). Insiders that own company stock include Morningside Venture Investment, Mark C Schiller and Michael Kauffman.
View institutional ownership trends.

How do I buy shares of Kezar Life Sciences?

Shares of KZR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Kezar Life Sciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Kezar Life Sciences investors own include Predictive Oncology (POAI), Ford Motor (F), JPMorgan Chase & Co. (JPM), Wells Fargo & Company (WFC), Bank of America (BAC), Abbott Laboratories (ABT) and Zomedica (ZOM).

Company Calendar

• Last Earnings: 11/12/2024
• Today: 11/20/2024
• Fiscal Year End: 12/31/2024
• Next Earnings (Estimated): 3/13/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:KZR
• CUSIP: N/A
• CIK: 1645666
• Web: www.kezarlifesciences.com
• Phone: (650) 822-5600
• Fax: N/A
• Employees: 60
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $40.50
• High Stock Price Target: $70.00
• Low Stock Price Target: $11.00
• Potential Upside/Downside: +440.7%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($13.18)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-101,870,000.00
• Net Margins: N/A
• Pretax Margin: -1,408.11%
• Return on Equity: -54.95%
• Return on Assets: -46.11%

Debt

• Debt-to-Equity Ratio: 0.05
• Current Ratio: 7.65
• Quick Ratio: 7.65

Sales & Book Value

• Annual Sales: $7 million
• Price / Sales: 7.81
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $25.80 per share
• Price / Book: 0.29

Miscellaneous

• Outstanding Shares: 7,300,000
• Free Float: 6,617,000
• Market Cap: $54.68 million
• Optionable: Not Optionable
• Beta: 0.22